[Click eStock] "BioSolution's 'Cartilife' Expands into China...Global Partnership Talks at BioUSA"

On June 11, independent research firm ValueFinder identified BioSolution's expansion into the Chinese market with its autologous cartilage cell therapy "Cartilife" and the broader development of its global business as the company's key growth drivers. In particular, the firm analyzed that the recent approval for sales in Hainan, China, and participation in BioUSA 2026 in the United States are expected to accelerate discussions on global partnerships.

BioSolution, a cell therapy specialist, was listed on the KOSDAQ in 2018 through a technology-based special listing. Its flagship product, the autologous cartilage cell therapy "Cartilife," received product approval from the Ministry of Food and Drug Safety in April last year, followed by sales approval for the Hainan Medical Special Zone in China this April. The company has set the local price in China at approximately 42 million won, aiming for a launch in the second half of this year. Local sales will be handled by a partner company, while BioSolution will receive a portion of the price as royalties.

The possibility of entering the mainland Chinese market is also gaining attention. China's government implemented the "New Biomedical Technology Regulation (Order 818)" in May 2026, which allows autologous cell therapies through a fast-track system similar to Korea's Advanced Regenerative Medicine Act. BioSolution, together with its local partner pharmaceutical company, is seeking to utilize this system to enter mainland China and is currently in talks with Guangzhou City for adoption. Guangzhou has a resident population of about 20 million, and the surrounding Guangdong province has a population of approximately 130 million. As the adoption is being led by the government, clinical procedures could be available in mainland China as early as 2027.

The company will also participate in BioUSA 2026, which will be held in San Diego, USA, from June 22 to 25. The main goal for this event is the technology transfer of Cartilife, while discussions on global partnerships for next-generation pipelines "Cartiloid" and "SpheroCure" will take place concurrently. Notably, the company has recently requested a Type C meeting with the U.S. Food and Drug Administration (FDA) to proceed with a Phase 3 clinical trial of Cartilife in the United States, drawing significant market interest in the potential for technology transfer negotiations.

The next-generation new drug pipeline "SpheroCure" is also raising expectations for growth. SpheroCure is a DMOAD-class therapy that slows the progression of osteoarthritis; it has demonstrated efficacy in its mechanism of action in preclinical studies with large animals such as goats. The company is currently awaiting approval for a domestic Phase 1/2a clinical trial (IND), and after approval, plans to apply for Korea's Advanced Regenerative Bio Act and simultaneously prepare for clinical trials in the United States.

Lee Chungheon, a researcher at ValueFinder, stated, "The sales approval for Cartilife in Hainan is significant as it marks the first gateway to entry into the Chinese market. With the simultaneous push for the Hainan launch and entry into the mainland based on Order 818, if the China discount is resolved around 2027, there is potential to enter a phase of substantial performance improvement."

He further added, "As global partnership discussions become more active through participation in BioUSA, and if SpheroCure's IND approval becomes visible, the possibility of reassessing the pipeline, including the value of technology transfer options, will increase even further."

There is growing optimism about BioSolution's overseas business expansion as the company advances both its entry into the Chinese market with Cartilife and global technology transfer discussions through BioUSA.

This content was produced with the assistance of AI translation services.